News & Topics
News&Topics

2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2017.10.16
Analyst Report[Full report]: Shared Research updates the report
2017.10.10
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.09.21
Analyst Report[Update report]: Shared Research updates the report
2017.09.21
Notice of Revision to the Earnings Forecast for FY2017
2017.09.21
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
2017.09.20
Analyst Report[Full report]: Shared Research updates the report
2017.08.31
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2017.08.30
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
2017.08.25
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.08.03
Analyst Report[Update report]: Shared Research updates the report
2017.08.03
Notice Concerning Non-operating Income
2017.08.03
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
2017.07.26
Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
2017.07.05
Dr. Koichi Takahashi, Assistant Professor, The University of Texas MD Anderson Cancer Center, has been appointed as a member of the SAB.
2017.06.30
Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.06.05
SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.06.05
Analyst Report[Full report]: Shared Research updates the report
2017.05.11
Analyst Report[Update report]: Shared Research updates the report
2017.05.11
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
2017.05.11
Notice Concerning Non-operating Expenses
2017.05.11
Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2017.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2017.03.30
Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders
2017.03.29
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
2017.03.29
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
2017.03.29
Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers
2017.03.28
Analyst Report[Full report]: Shared Research updates the report
2017.03.06
Information on Shareholders' Meeting: Updated the Page
2017.02.24
Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates
2017.02.24
Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment
2017.02.09
Analyst Report[Update report]: Shared Research updates the report
2017.02.09
SymBio's Mid-Range Plan: FY2017 to FY2019
2017.02.09
Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated)
2017.02.09
Notice Concerning Non-Operating Income
2017.02.01
Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2017.01.31
Japan Launch of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg